Dr. Berardi completed his Hematopathology and Transfusion Medicine training in Ottawa and is now a staff Hematopathologist at the Ottawa Hospital. He holds a PhD in Biochemistry & Molecular Biology from the University of Calgary.
This presentation will focus on the changing landscape of molecular diagnostic testing for hematolymphoid neoplasms.
Emphasis will be placed on best practices for interpreting molecular diagnostic tests and ways to communicate these results
to optimize patient care
Explain the principles of molecular diagnostic testing as applies to complex malignant hematology and recommend
specimen requirements needed for accurate results.
Differentiate between clinically actionable mutations and predictive markers and describe how these can influence clinical
decision-making in routine practice.
Discuss myeloid neoplasms arising in the setting of germline predisposition and adopting a strategy to managing these
Outline a general approach to laboratory management and quality assurance as it pertains to molecular diagnostics.